Albert Seymour received his undergraduate degree in Biology from the University of Delaware and MS degree in Molecular Biology from Johns Hopkins University where he focused on the molecular genetics of cancer in the laboratory of Dr. Bert Vogelstein. He then went on to receive his PhD and post-doctoral training in Human Genetics at the University of Pittsburgh under the direction of Dr. Michael Gorin where he studied the genetics of rare ophthalmic disease.
In 1997, Albert took a position at Pfizer in Groton, CT where he spent the next 14 years directing his team in the application of human genetics and computational biology to discover and develop novel therapeutics aimed at targeting diabetes, inflammatory diseases, and cancer.
In 2011, Albert moved to Shire in Lexington, MA as the Head of Drug Discovery and Translational Research where, in three years, he doubled the rare disease Discovery portfolio. In 2014, Albert assumed the role as the Global Head of Research and Nonclinical Development. In this role, he leads a team of scientists who are responsible for delivering a sustained portfolio of rare disease focused therapeutic projects from idea to IND. In addition his team supports Shires R&D portfolio across all therapeutic areas with bioanalytics, toxicology, and DMPK.
